Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Revenue

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
India Formulations Revenue	192.90B	169.23B
India Formulations Revenue Growth	13.99%	13.66%
US Formulations Revenue	168.24B	162.40B
US Formulations Revenue Growth	3.60%	5.80%
Emerging Market Revenue	111.87B	94.16B
Emerging Market Revenue Growth	18.80%	9.24%
Rest of the World Formulations Revenue	85.68B	71.63B
Rest of the World Formulations Revenue Growth	19.63%	6.70%
Total Formulations Revenue	558.70B	497.42B
Total Formulations Revenue Growth	12.32%	9.15%
Active Pharmaceutical Ingredients (API) Revenue	21.85B	21.29B
Active Pharmaceutical Ingredients (API) Revenue Growth	2.63%	10.97%
Others Segment Revenue	1.65B	1.70B
Others Segment Revenue Growth	-2.81%	-36.74%
Other Operating Revenue	2.42B	5.37B
Other Operating Revenue Growth	-54.96%	-27.25%

Key Performance Indicators

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Number of Medical Representatives	15.11K
Number of Medical Representatives Growth	8.04%
Sales per Medical Representative	11.20M
Sales per Medical Representative Growth	5.66%

Updated Mar 31, 2026. Data Source: Fiscal.ai.